2022
Pneumonitis in immunotherapy alone vs. chemoimmunotherapy: A systematic review and meta-analysis.
Barbaro A, Siskin M, Grello C, Hernandez A, Dublin J, Breslin S, Punekar S, Velcheti V. Pneumonitis in immunotherapy alone vs. chemoimmunotherapy: A systematic review and meta-analysis. Journal Of Clinical Oncology 2022, 40: e21120-e21120. DOI: 10.1200/jco.2022.40.16_suppl.e21120.Peer-Reviewed Original ResearchNon-small cell lung cancerImmune related adverse eventsImmune checkpoint inhibitorsAdvanced non-small cell lung cancerSevere pneumonitisPD-L1Combination therapyCTLA-4Use of ICIsCombination immune checkpoint inhibitorsLife-threatening complicationsRelated adverse eventsCell lung cancerLung cancer patientsT cell populationsInverse variance weightingGrade pneumonitisCheckpoint inhibitorsInterventional armAdverse eventsCytotoxic chemotherapyImmune suppressionCancer patientsLung cancerClinical trialsPD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy.
Shu F, Punekar S, Velcheti V, Sanmamed M, Wang J. PD-L1 Crosslinking as a New Strategy of 4-1BB Agonism Immunotherapy. Clinical Cancer Research 2022, 28: 3182-3184. PMID: 35648093, DOI: 10.1158/1078-0432.ccr-22-0541.Peer-Reviewed Original Research
2021
Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer
Punekar S, Castillo R, Sandigursky S, Cho D. Role of IVIG in the Treatment of Autoimmune Conditions With Concurrent Immune Checkpoint Inhibitors for Metastatic Cancer. Journal Of Immunotherapy 2021, 44: 335-337. PMID: 34166301, DOI: 10.1097/cji.0000000000000380.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsCheckpoint inhibitorsAutoimmune conditionsDiscontinuation of ICIsPD-1/PD-L1Concurrent immune checkpoint inhibitorsImmune-related adverse eventsMetastatic renal cell carcinomaRole of IVIgUnderlying autoimmune conditionClasses of medicationsRenal cell carcinomaParaneoplastic dermatomyositisIntravenous immunoglobulinAdverse eventsPD-L1Antitumor responseCell carcinomaImmunomodulatory agentsMetastatic cancerImmune pathwaysExacerbationPatientsTreatmentCancer